83.48
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Medtronic Plc stock is traded at $83.48, with a volume of 6.33M.
It is down -0.17% in the last 24 hours and down -2.11% over the past month.
One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, transcatheter heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company primarily markets its products to healthcare institutions and physicians in the United States, Western Europe, and Japan. Foreign sales account for roughly 50% of the company's total sales.
See More
Previous Close:
$83.62
Open:
$83.5
24h Volume:
6.33M
Relative Volume:
0.91
Market Cap:
$108.82B
Revenue:
$33.20B
Net Income/Loss:
$4.26B
P/E Ratio:
25.37
EPS:
3.29
Net Cash Flow:
$5.47B
1W Performance:
-1.61%
1M Performance:
-2.11%
6M Performance:
-4.83%
1Y Performance:
+0.87%
Medtronic Plc Stock (MDT) Company Profile
Name
Medtronic Plc
Sector
Industry
Phone
01135314381700
Address
BUILDING TWO PARKMORE BUSINESS PARK WEST, GALWAY
Compare MDT with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
MDT
Medtronic Plc
|
83.48 | 108.82B | 33.20B | 4.26B | 5.47B | 3.29 |
![]()
ABT
Abbott Laboratories
|
133.24 | 231.09B | 42.34B | 13.50B | 6.66B | 7.71 |
![]()
BSX
Boston Scientific Corp
|
102.86 | 155.24B | 17.55B | 2.03B | 2.72B | 1.37 |
![]()
SYK
Stryker Corp
|
380.92 | 144.54B | 23.22B | 2.86B | 3.58B | 7.40 |
![]()
EW
Edwards Lifesciences Corp
|
73.68 | 44.31B | 5.54B | 4.18B | 623.10M | 7.00 |
Medtronic Plc Stock (MDT) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Mar-04-25 | Upgrade | Citigroup | Neutral → Buy |
Oct-10-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
Aug-21-24 | Reiterated | Oppenheimer | Perform |
Aug-15-24 | Upgrade | UBS | Sell → Neutral |
Aug-14-24 | Downgrade | Stifel | Buy → Hold |
May-30-24 | Initiated | Goldman | Sell |
Jul-19-23 | Initiated | Robert W. Baird | Neutral |
Jun-30-23 | Initiated | CL King | Buy |
May-30-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Apr-24-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
Mar-29-23 | Downgrade | UBS | Buy → Sell |
Jan-09-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
Nov-23-22 | Downgrade | Citigroup | Buy → Neutral |
Nov-23-22 | Downgrade | Oppenheimer | Outperform → Perform |
Nov-16-22 | Downgrade | Deutsche Bank | Buy → Hold |
Oct-18-22 | Initiated | Barclays | Equal Weight |
Oct-13-22 | Initiated | Mizuho | Buy |
Oct-12-22 | Initiated | Jefferies | Hold |
Aug-24-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
Jul-06-22 | Initiated | Wolfe Research | Underperform |
Jun-01-22 | Downgrade | Atlantic Equities | Overweight → Neutral |
May-27-22 | Downgrade | Needham | Buy → Hold |
Apr-13-22 | Downgrade | Truist | Buy → Hold |
Mar-02-22 | Resumed | BofA Securities | Buy |
Jan-10-22 | Downgrade | BTIG Research | Buy → Neutral |
Jan-07-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Jan-04-22 | Downgrade | Piper Sandler | Overweight → Neutral |
Dec-17-21 | Downgrade | JP Morgan | Overweight → Neutral |
Dec-16-21 | Downgrade | Wells Fargo | Overweight → Equal Weight |
Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
Jun-10-21 | Resumed | Cowen | Outperform |
May-25-21 | Initiated | Barclays | Equal Weight |
Apr-15-21 | Initiated | Atlantic Equities | Overweight |
Dec-15-20 | Upgrade | Goldman | Sell → Neutral |
Dec-15-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Oct-08-20 | Upgrade | Bernstein | Mkt Perform → Outperform |
Oct-08-20 | Upgrade | Stifel | Hold → Buy |
Sep-11-20 | Initiated | Wolfe Research | Peer Perform |
May-14-20 | Downgrade | DZ Bank | Buy → Hold |
Mar-30-20 | Downgrade | Needham | Strong Buy → Buy |
Mar-25-20 | Upgrade | DZ Bank | Hold → Buy |
Mar-05-20 | Initiated | Citigroup | Buy |
Feb-13-20 | Initiated | Goldman | Sell |
Jan-08-20 | Initiated | SunTrust | Buy |
Jan-02-20 | Upgrade | Guggenheim | Neutral → Buy |
Jun-05-19 | Upgrade | Wells Fargo | Market Perform → Outperform |
Feb-04-19 | Reiterated | Needham | Strong Buy |
Jan-03-19 | Initiated | Deutsche Bank | Buy |
Jan-02-19 | Downgrade | Citigroup | Buy → Neutral |
Dec-19-18 | Upgrade | JP Morgan | Neutral → Overweight |
Nov-28-18 | Initiated | UBS | Buy |
Oct-16-18 | Initiated | Barclays | Overweight |
Aug-27-18 | Reiterated | Argus | Buy |
View All
Medtronic Plc Stock (MDT) Latest News
Healthcare Digital Twins Market Size to Hit USD 6.80 Billion by 2032, growing at 25.7% CAGR, says Coherent Market Insights - GlobeNewswire Inc.
Medtronic plc (MDT): Among the Best High-Yield Dividend Stocks for 2025 and Beyond - Yahoo Finance
Is Medtronic plc (MDT) the Best Medical Device Stock to Buy Now? - Insider Monkey
Medtronic (MDT) Rises Yet Lags Behind Market: Some Facts Worth Knowing - Nasdaq
Is Medtronic Stock a Buy Pre-Q4 Earnings? Key Metrics to Watch - The Globe and Mail
Medtronic to announce financial results for its fourth quarter and full fiscal year 2025 - The Globe and Mail
11 Best Medical Device Stocks to Buy Now - Insider Monkey
New survey: 1 in 3 women have not talked to their doctor about heart health, the #1 killer of women - Medtronic
What Are Wall Street Analysts’ Target Price for Medtronic Stock? - MSN
Urology Surgical Instruments Market Top PlayersMedtronic, - openPR.com
Medtronic To Announce Financial Results For Its Fourth Quarter And Full Fiscal Year 2025 - Barchart.com
Intubation Tubes Market Detailed in New Research Report By 2032 | - openPR.com
Medtronic (MDT) Surpasses Market Returns: Some Facts Worth Knowing - Yahoo Finance
A Look At The Fair Value Of Medtronic plc (NYSE:MDT) - Yahoo Finance
Medtronic (MDT) Rises Higher Than Market: Key Facts - Yahoo Finance
Medtronic wins FDA approval for defibrillation lead - MedTech Dive
Medtronic Education Program Opens Doors for Employees - Yahoo Finance
Medtronic study backs automated neuromod for overactive bladder - MassDevice
Medtronic and Abbott's game-changing partnership for CGM integration - Today's Medical Developments
4 PFA studies in the spotlight at Heart Rhythm 2025 - MedTech Dive
Earnings Preview: What To Expect From Medtronic’s Report - Nasdaq
Medtronic Gets FDA Nod for Smallest-Diameter, Lumenless Defibrillation Lead - Diagnostic and Interventional Cardiology
Medtronic has positive VenaSeal data - MassDevice
Functional Endoscopic Sinus Surgery Market Key Players - openPR.com
Medtronic submits Hugo soft tissue robot for FDA approval - MedTech Dive
Medtronic inks new distro agreement for Retia Medical Argos cardiac output monitor - MassDevice
The Zacks Analyst Blog Highlights Abbott Laboratories, Boston Scientific and Medtronic - Zacks Investment Research
Medtronic Trial for Robotic-Assisted Surgery System Meets Safety, Effectiveness Primary Endpoints - marketscreener.com
Medtronic’s defibrillation lead gains FDA approval for use in right ventricle - Yahoo Finance
Medtronic Files for FDA Submission for the Hugo Robotic System - Medical Device and Diagnostic industry
Medtronic Affera™ pulsed field ablation technologies continue to demonstrate promising evidence for atrial fibrillation patients - BioSpace
Smoke Evacuation System Market to Garner $196.4 Million by 2027 | - openPR.com
Medtronic receives US FDA approval for smallest-diameter, lumenless defibrillation lead, the OmniaSecure lead - Pharmabiz.com
Medtronic (MDT) Showcases Positive AFib Treatment Results at Key Medical Conference | MDT Stock News - GuruFocus
Medtronic (MDT) Reveals Promising AFib Treatment Outcomes with S - GuruFocus
Medtronic reports more positive outcomes with Affera PFA tech - MassDevice
Medtronic Affera pulsed field ablation technologies continue to demonstrate promising evidence for atrial fibrillation patients - Investing News Network
Medtronic PLC Says Sphere-360 Study Shows 88% Freedom From Arrhythmia Recurrence - marketscreener.com
Medtronic submits Hugo surgical robot to FDA, meets trial endpoints - MassDevice
Medtronic (MDT) Seeks FDA Approval for Hugo Robotic Surgery Syst - GuruFocus
Medtronic seeks FDA nod for Hugo robotic surgery system (MDT) - Seeking Alpha
Medtronic Expand URO U.S. clinical trial meets safety and effectiveness primary endpoints for Hugo™ robotic-assisted surgery systemApr 26, 2025 - Medtronic
Medtronic (NYSE:MDT) Secures FDA Approval For Innovative OmniaSecure Defibrillation Lead - Yahoo Finance
Medtronic wins FDA nod for world’s smallest defibrillation lead - MassDevice
Medtronic (MDT) Gains FDA Approval for Advanced Defibrillation L - GuruFocus
Medtronic Plc Stock (MDT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):